In summary, this preliminary clinical study confirmed the utility of the new compound [18F]-APN-1607 for the detection of tau pathology and reinforced previous studies showing an overlap between cerebral glucose hypometabolism (using [18F]-FDG PET) and tau deposition and their association with dementia. The gene discussed is MAPT; the disease is dementia.